Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

Activating mutations in BRAF kinase are common in melanomas. Clinical trials with PLX4032, the mutant-BRAF inhibitor, show promising preliminary results in patients selected for the presence of V600E mutation. However, activating V600K mutation is the other most common mutation, yet patients with th...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubinstein, Jill C, Sznol, Mario, Pavlick, Anna C, Ariyan, Stephan, Cheng, Elaine, Bacchiocchi, Antonella, Kluger, Harriet M, Narayan, Deepak, Halaban, Ruth
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917408/
https://www.ncbi.nlm.nih.gov/pubmed/20630094
http://dx.doi.org/10.1186/1479-5876-8-67

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917408/
https://www.ncbi.nlm.nih.gov/pubmed/20630094
http://dx.doi.org/10.1186/1479-5876-8-67

Ejemplares similares